Press Release History - 2018

  • 21 Jun 2018
    ThromboGenics Partners with Prevent Blindness at 2018 Focus on Eye Health National Summit in Washington DC
  • 25 May 2018
    ThromboGenics Enrolls First Patient in Phase 1 Clinical Study Evaluating THR-149, a plasma kallikrein inhibitor, for treatment of Diabetic Macular Edema (DME)
  • 23 May 2018
    ThromboGenics to present a preclinical overview of its two most advanced diabetic eye disease clinical candidates, THR-317 and THR-149, at EASDec 2018
  • 14 May 2018
    ThromboGenics Presenting Industry Expertise and Developments at Bio€quity Europe and Knowledge for Growth meetings in Ghent, Belgium
  • 9 May 2018
    ThromboGenics Business Update – Q1 2018
  • 27 Apr 2018
    ThromboGenics Initiates Phase 2 Clinical Study Evaluating anti-PlGF (THR-317) in combo with anti-VEGF (ranibizumab) for treatment of DME
  • 6 Apr 2018
    ThromboGenics announces publication in The Journal of Medicinal Chemistry of preclinical data supporting therapeutic potential of THR-149
  • 4 Apr 2018
    ThromboGenics Reports Initial Data from its Clinical Study evaluating THR-317 for the Treatment of Diabetic Macular Edema (DME)
  • 15 Mar 2018
    ThromboGenics Business Update – FY 2017
  • 30 Jan 2018
    Disclosure in accordance with Belgian Law of 2 May 2007
  • 26 Jan 2018
    NOVARTIS PHARMA AG HOLDING 5.69% OF THROMBOGENICS EQUITY CAPITAL